Free Trial

Oncolytics Biotech (ONCY) Competitors

Oncolytics Biotech logo
$1.05 -0.09 (-7.89%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$1.06 +0.00 (+0.48%)
As of 07/25/2025 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ONCY vs. KMDA, TERN, RGNX, SVRA, TECX, FULC, SLDB, PASG, PRTC, and SNDL

Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Kamada (KMDA), Terns Pharmaceuticals (TERN), REGENXBIO (RGNX), Savara (SVRA), Tectonic Therapeutic (TECX), Fulcrum Therapeutics (FULC), Solid Biosciences (SLDB), Passage Bio (PASG), PureTech Health (PRTC), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry.

Oncolytics Biotech vs. Its Competitors

Kamada (NASDAQ:KMDA) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

20.4% of Kamada shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Kamada currently has a consensus target price of $13.00, indicating a potential upside of 68.39%. Oncolytics Biotech has a consensus target price of $4.33, indicating a potential upside of 312.70%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than Kamada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kamada
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Oncolytics Biotech
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Kamada has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

In the previous week, Oncolytics Biotech had 5 more articles in the media than Kamada. MarketBeat recorded 7 mentions for Oncolytics Biotech and 2 mentions for Kamada. Kamada's average media sentiment score of 1.78 beat Oncolytics Biotech's score of 0.11 indicating that Kamada is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kamada
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Oncolytics Biotech
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Kamada has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kamada$160.95M2.76$14.46M$0.2926.62
Oncolytics BiotechN/AN/A-$23.14M-$0.29-3.62

Kamada has a net margin of 9.60% compared to Oncolytics Biotech's net margin of 0.00%. Kamada's return on equity of 6.31% beat Oncolytics Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Kamada9.60% 6.31% 4.43%
Oncolytics Biotech N/A -313.77%-130.19%

Summary

Kamada beats Oncolytics Biotech on 10 of the 15 factors compared between the two stocks.

Get Oncolytics Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONCY vs. The Competition

MetricOncolytics BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$107.48M$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E Ratio-3.6221.1828.1020.05
Price / SalesN/A288.50432.4490.07
Price / CashN/A42.7636.2258.56
Price / Book21.008.378.665.87
Net Income-$23.14M-$55.19M$3.25B$258.55M
7 Day Performance-17.32%5.88%4.23%3.74%
1 Month Performance45.83%17.33%10.52%11.75%
1 Year Performance0.96%4.42%34.41%18.03%

Oncolytics Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONCY
Oncolytics Biotech
1.8147 of 5 stars
$1.05
-7.9%
$4.33
+312.7%
+1.0%$107.48MN/A-3.6230News Coverage
Upcoming Earnings
KMDA
Kamada
4.3245 of 5 stars
$7.78
+0.4%
$13.00
+67.1%
+30.0%$447.39M$167.24M26.83360News Coverage
Positive News
TERN
Terns Pharmaceuticals
3.9798 of 5 stars
$5.11
+4.3%
$15.63
+205.8%
-31.2%$446.31MN/A-4.6940
RGNX
REGENXBIO
4.2825 of 5 stars
$8.70
+0.2%
$31.63
+263.5%
-37.7%$436.39M$83.33M-2.80370News Coverage
Positive News
SVRA
Savara
1.8749 of 5 stars
$2.51
+5.0%
$5.60
+123.1%
-43.7%$433.83MN/A-5.2320Positive News
TECX
Tectonic Therapeutic
2.7025 of 5 stars
$23.12
+2.1%
$83.60
+261.6%
+31.3%$431.72MN/A-3.16120Analyst Downgrade
FULC
Fulcrum Therapeutics
0.4921 of 5 stars
$7.90
+0.9%
$6.29
-20.4%
-9.6%$426.44M$80M-112.84100Upcoming Earnings
SLDB
Solid Biosciences
3.0988 of 5 stars
$5.47
+4.0%
$15.10
+176.1%
-22.7%$423.98M$8.09M-1.83100
PASG
Passage Bio
3.3868 of 5 stars
$6.79
-15.3%
$150.00
+2,109.1%
-57.7%$423.76MN/A-6.66130News Coverage
Positive News
Insider Trade
Gap Up
High Trading Volume
PRTC
PureTech Health
2.785 of 5 stars
$17.56
-1.4%
$45.00
+156.3%
-14.4%$421.65M$4.32M0.00100Positive News
Upcoming Earnings
SNDL
SNDL
1.7229 of 5 stars
$1.58
+13.7%
$3.63
+129.4%
-28.9%$415.19M$671.81M-5.452,516News Coverage
Upcoming Earnings
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ONCY) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners